Clinical Trial Update: Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients [Phase 2]

View source ↗

Summary

Phase II study evaluating Pazopanib as a second-line treatment after sunitinib in patients with metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Votrient (Pazopanib)

Snippet

Sponsor: Southern China Urology Cancer Consortium | Conditions: Self Efficacy, Adverse Drug Event | Phase 2 | Status: UNKNOWN